These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24756216)

  • 1. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.
    Davidson B; Nymoen DA; Elgaaen BV; Staff AC; Tropé CG; Kærn J; Reich R; Falkenthal TE
    Virchows Arch; 2014 Jun; 464(6):701-7. PubMed ID: 24756216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
    Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
    Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
    Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
    Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
    Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
    Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
    Vaksman O; Davidson B; Tropé C; Reich R
    Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.
    Davidson B; Holth A; Nguyen MT; Tropé CG; Wu C
    Gynecol Oncol; 2013 Feb; 128(2):364-70. PubMed ID: 23099104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
    Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
    Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.
    Stavnes HT; Nymoen DA; Langerød A; Holth A; Børresen Dale AL; Davidson B
    Virchows Arch; 2013 Feb; 462(2):163-73. PubMed ID: 23242172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
    Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
    Broner EC; Tropé CG; Reich R; Davidson B
    Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
    Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
    Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
    Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
    Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
    Davidson B; Goldberg I; Berner A; Kristensen GB; Reich R
    Clin Exp Metastasis; 2003; 20(2):161-9. PubMed ID: 12705637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
    Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
    Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.